Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October

Shares of Clovis Oncology (NASDAQ: CLVS) lost over 60% of their value last month, according to data provided by S&P Global Market Intelligence. While investors might expect a drop of that magnitude for a development-stage biopharma reporting that an important drug had failed in the clinic, that wasn't the case here.